Rigel Pharmaceuticals Inc. has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist who brings to Rigel more than 25 years of experience developing cellular immunotherapies to treat cancer and portfolio strategy. https://lnkd.in/gxEJ9xwm
Rigel Pharmaceuticals Inc.
生物技术研究
South San Francisco，CA 10,153 位关注者
A biotechnology company dedicated to providing small molecule drugs that significantly improve the lives of patients.
关于我们
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients hematologic disorders, cancer and rare immune diseases.
- 网站
-
https://www.rigel.com
Rigel Pharmaceuticals Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，CA
- 类型
- 上市公司
- 创立
- 1996
地点
-
主要
获取路线
1180 Veterans Blvd
US，CA，South San Francisco，94080
Rigel Pharmaceuticals Inc.员工
-
Gary Westemeyer
Oncology Account Manager | Hematology Oncology | Ultra Rare Disease | IDNs | Institutional Sales | Buy & Bill
-
Jane Wasman
Experienced corporate board chair/life sciences executive/executive advisor
-
Mimi Lin Park
Director, Development Project Management at Rigel Pharmaceuticals Inc.
-
Esteban Masuda
Executive Vice President & Head of Research at Rigel Pharmaceuticals Inc. at Rigel Pharmaceuticals Inc.
动态
-
On?#employeeappreciationday?we recognize our Rigel employees and their commitment to living our Values.?Rigel’s success is due to your contributions and teamwork. We are ONE! Thank you!
-
-
Imagine a gender equal world. A world free of bias, stereotypes, and discrimination.?March 8th is International Women’s Day #IWD2025 – a day to celebrate women's achievement, raise awareness and take action to forge gender parity.?Learn more about International Women’s Day at: https://lnkd.in/dGX7T8X #AccelerateAction #IWD2025
-
-
Today, $RIGL will report Fourth Quarter and Full Year 2024 financial results and a business update https://lnkd.in/g6AAmFhf
-
-
Today is Rare Disease Day, to raise awareness and improve the lives of this vulnerable population who require immediate and urgent attention. For more information go to: https://lnkd.in/e76yAESx
-
-
Rigel Pharmaceuticals Inc. Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update https://lnkd.in/gVjyS5Ta
-
-
$RIGL partner Kissei published long-term results from a Phase 3 clinical study of fostamatinib conducted in Japanese patients for treatment of ITP in the International Journal of Hematology https://lnkd.in/gzunmUrQ
-
-
Today is #WorldCancerDay, an international day to raise awareness of cancer and to encourage its prevention. This year, it is all about people-centered cancer care. Learn more at: https://lnkd.in/gAJXpEer
-
-
Rigel Pharmaceuticals Inc. announced first patient enrolled in NIH/NHLBI-sponsored Phase 1 study evaluating fostamatinib, the company's oral spleen tyrosine kinase (SYK) inhibitor, in patients with sickle cell disease https://lnkd.in/gUUgCSgv
-
-
Rigel Pharmaceuticals Inc. partner Kissei announces approval of TAVALISSE (fostamatinib) for the treatment of chronic ITP in South Korea. For more information: https://lnkd.in/gvE_3Rb8
-